文献速递白血病

STAT5对IL-7介导的T细胞急性淋巴细胞白血病细胞存活、生长和增殖至关重要

STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
PubMed 文献 · Blood Adv · 2018-01-01

该研究探讨STAT5是否介导IL-7对T细胞急性淋巴细胞白血病(T-ALL)细胞的促白血病效应。结果显示IL-7诱导T-ALL细胞STAT通路活化,STAT5失活可阻止IL-7介导的T-ALL细胞存活、生长和增殖;STAT5通过上调PIM1等机制发挥作用,PIM1药理学抑制可消除IL-7介导的T-ALL细胞增殖。

要点

  • IL-7诱导T-ALL细胞STAT通路活化,STAT5失活阻止IL-7介导的T-ALL细胞存活、生长和增殖。
  • STAT5为IL-7诱导的p27kip1下调和转铁蛋白受体CD71上调所必需。
  • PIM1药理学抑制可消除IL-7介导的T-ALL细胞增殖。

核心结论

  • STAT5部分通过上调PIM1活性,在介导IL-7/IL-7R的促白血病效应中起主要作用。

研究设计与样本

  • 本文为体外研究,使用T-ALL细胞探讨STAT5在IL-7介导的T-ALL细胞效应中的作用。

主要发现

  • IL-7诱导T-ALL细胞STAT通路活化,STAT5失活阻止IL-7介导的T-ALL细胞存活、生长和增殖。
  • STAT5为IL-7诱导的p27kip1下调和CD71上调所必需。
  • STAT5抑制对IL-7介导的Bcl-2上调无显著影响,提示与正常T细胞不同,STAT5通过不依赖Bcl-2的机制促进白血病细胞存活。
  • STAT5染色质免疫沉淀测序和RNA测序揭示T-ALL细胞中IL-7驱动的STAT5依赖性转录程序,包括通过选择性转录使BCL6失活和上调致癌性丝氨酸/苏氨酸激酶PIM1。
  • PIM1药理学抑制可消除IL-7介导的T-ALL细胞增殖。

临床怎么用

  • 作者认为,涉及使用PIM激酶小分子抑制剂的策略可能对大多数依赖IL-7受体(IL-7R)信号的白血病具有治疗潜力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell acute lymphoblastic leukemia (T-ALL) constitutes an aggressive subset of ALL, the most frequent childhood malignancy. Whereas interleukin-7 (IL-7) is essential for normal T-cell development, it can also accelerate T-ALL development in vivo and leukemia cell survival and proliferation by activating phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling. Here, we investigated whether STAT5 could also mediate IL-7 T-ALL-promoting effects. We show that IL-7 induces STAT pathway activation in T-ALL cells and that STAT5 inactivation prevents IL-7-mediated T-ALL cell viability, growth, and proliferation. At the molecular level, STAT5 is required for IL-7-induced downregulation of p27kip1 and upregulation of the transferrin receptor, CD71. Surprisingly, STAT5 inhibition does not significantly affect IL-7-mediated Bcl-2 upregulation, suggesting that, contrary to normal T-cells, STAT5 promotes leukemia cell survival through a Bcl-2-independent mechanism. STAT5 chromatin immunoprecipitation sequencing and RNA sequencing reveal a diverse IL-7-driven STAT5-dependent transcriptional program in T-ALL cells, which includes BCL6 inactivation by alternative transcription and upregulation of the oncogenic serine/threonine kinase PIM1 Pharmacological inhibition of PIM1 abrogates IL-7-mediated proliferation on T-ALL cells, indicating that strategies involving the use of PIM kinase small-molecule inhibitors may have therapeutic potential against a majority of leukemias that rely on IL-7 receptor (IL-7R) signaling. Overall, our results demonstrate that STAT5, in part by upregulating PIM1 activity, plays a major role in mediating the leukemia-promoting effects of IL-7/IL-7R.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ribeiro D, Melão A, van Boxtel R, et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2018. PMID: 30185437. doi:10.1182/bloodadvances.2018021063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。